ClinVar Genomic variation as it relates to human health
NM_001122955.4(BSCL2):c.455A>G (p.Asn152Ser)
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_001122955.4(BSCL2):c.455A>G (p.Asn152Ser)
Variation ID: 4543 Accession: VCV000004543.96
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 11q12.3 11: 62702499 (GRCh38) [ NCBI UCSC ] 11: 62469971 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Sep 4, 2014 Oct 20, 2024 Dec 14, 2023 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_001122955.4:c.455A>G MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_001116427.1:p.Asn152Ser missense NM_001130702.2:c.263A>G NP_001124174.2:p.Asn88Ser missense NM_001386027.1:c.455A>G NP_001372956.1:p.Asn152Ser missense NM_001386028.1:c.455A>G NP_001372957.1:p.Asn152Ser missense NM_032667.6:c.263A>G NP_116056.3:p.Asn88Ser missense NR_037946.1:n.2975A>G non-coding transcript variant NC_000011.10:g.62702499T>C NC_000011.9:g.62469971T>C NG_008461.1:g.12076A>G LRG_235:g.12076A>G LRG_235t1:c.455A>G LRG_235p1:p.Asn152Ser LRG_235t2:c.263A>G LRG_235p2:p.Asn88Ser Q96G97:p.Asn88Ser - Protein change
- N88S, N152S
- Other names
-
NM_001122955.3(BSCL2):c.455A>G(p.Asn152Ser)
NM_001130702.2(BSCL2):c.263A>G(p.Asn88Ser)
NM_032667.6(BSCL2):c.263A>G(p.Asn88Ser)
- Canonical SPDI
- NC_000011.10:62702498:T:C
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
- -
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
Trans-Omics for Precision Medicine (TOPMed) 0.00000
Exome Aggregation Consortium (ExAC) 0.00001
The Genome Aggregation Database (gnomAD), exomes 0.00002
- Links
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
BSCL2 | - | - |
GRCh38 GRCh37 |
8 | 575 | |
HNRNPUL2-BSCL2 | - | - | - | GRCh38 | - | 605 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Pathogenic (5) |
criteria provided, multiple submitters, no conflicts
|
Apr 27, 2023 | RCV000004801.19 | |
Pathogenic (2) |
criteria provided, single submitter
|
Oct 9, 2018 | RCV000004802.18 | |
Pathogenic (1) |
criteria provided, single submitter
|
Dec 14, 2023 | RCV000168078.19 | |
Pathogenic (1) |
criteria provided, single submitter
|
Sep 19, 2016 | RCV000507071.16 | |
Pathogenic (7) |
criteria provided, multiple submitters, no conflicts
|
May 29, 2023 | RCV000340485.35 | |
Pathogenic (3) |
criteria provided, multiple submitters, no conflicts
|
Jun 17, 2022 | RCV001270680.15 | |
Pathogenic (1) |
criteria provided, single submitter
|
Jun 6, 2023 | RCV002426488.10 | |
Pathogenic (1) |
criteria provided, single submitter
|
Sep 24, 2020 | RCV001847582.10 | |
Uncertain significance (1) |
no assertion criteria provided
|
Jan 6, 2016 | RCV003311646.8 | |
Pathogenic (1) |
criteria provided, single submitter
|
Jul 10, 2021 | RCV001813949.8 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Pathogenic
(Sep 19, 2016)
|
criteria provided, single submitter
Method: clinical testing
|
not specified
Affected status: unknown
Allele origin:
germline
|
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Accession: SCV000602892.1
First in ClinVar: Sep 30, 2017 Last updated: Sep 30, 2017 |
|
|
Pathogenic
(Oct 09, 2018)
|
criteria provided, single submitter
Method: clinical testing
|
Neuronopathy, distal hereditary motor, type 5A
Affected status: yes
Allele origin:
paternal
|
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne
Accession: SCV000966217.1
First in ClinVar: Aug 26, 2019 Last updated: Aug 26, 2019 |
|
|
Pathogenic
(Oct 23, 2020)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
(Autosomal unknown)
Affected status: yes
Allele origin:
germline
|
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen
Accession: SCV001446866.1
First in ClinVar: Nov 28, 2020 Last updated: Nov 28, 2020 |
Clinical Features:
Spasticity (present) , Spastic paraplegia (present) , Urinary retention (present) , Brisk reflexes (present) , Impaired vibration sensation in the lower limbs (present) , Babinski … (more)
Spasticity (present) , Spastic paraplegia (present) , Urinary retention (present) , Brisk reflexes (present) , Impaired vibration sensation in the lower limbs (present) , Babinski sign (present) , Progressive spastic paraparesis (present) (less)
Sex: male
|
|
Pathogenic
(Jul 10, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Peripheral neuropathy
Affected status: yes
Allele origin:
germline
|
Kariminejad - Najmabadi Pathology & Genetics Center
Accession: SCV001755663.1
First in ClinVar: Jan 22, 2022 Last updated: Jan 22, 2022 |
|
|
Pathogenic
(Sep 24, 2020)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary spastic paraplegia
Affected status: yes
Allele origin:
germline
|
Genome Diagnostics Laboratory, The Hospital for Sick Children
Accession: SCV002106254.1
First in ClinVar: Mar 19, 2022 Last updated: Mar 19, 2022 |
|
|
Pathogenic
(Jun 17, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Neuronopathy, distal hereditary motor, type 5C
Affected status: yes
Allele origin:
germline
|
MGZ Medical Genetics Center
Accession: SCV002580923.1
First in ClinVar: Oct 15, 2022 Last updated: Oct 15, 2022
Comment:
ACMG criteria applied: PS4, PP1_STR, PS3_MOD, PM2_SUP, PP3
|
Number of individuals with the variant: 2
Sex: male
|
|
Pathogenic
(Apr 30, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Neuronopathy, distal hereditary motor, type 5C
(Autosomal dominant inheritance)
Affected status: yes
Allele origin:
germline
|
Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München
Accession: SCV002764943.1
First in ClinVar: Dec 24, 2022 Last updated: Dec 24, 2022 |
Number of individuals with the variant: 1
Clinical Features:
Amyotrophy involving the shoulder musculature (present) , Amyotrophic lateral sclerosis (present) , Distal amyotrophy (present) , Muscle weakness (present)
|
|
Pathogenic
(Apr 27, 2023)
|
criteria provided, single submitter
Method: research
|
Hereditary spastic paraplegia 17
Affected status: yes
Allele origin:
germline
|
Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL)
Accession: SCV003920745.1
First in ClinVar: Nov 04, 2023 Last updated: Nov 04, 2023 |
Number of individuals with the variant: 4
|
|
Pathogenic
(Dec 14, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Charcot-Marie-Tooth disease type 2
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV000218732.12
First in ClinVar: Mar 29, 2015 Last updated: Feb 20, 2024 |
Comment:
This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 88 of the BSCL2 protein (p.Asn88Ser). … (more)
This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 88 of the BSCL2 protein (p.Asn88Ser). This variant is present in population databases (rs137852972, gnomAD 0.01%). This missense change has been observed in individuals with autosomal dominant BSCL2-related conditions (PMID: 14981520, 15732094, 16427281, 20598714, 23553728, 25219579, 25454168). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 4543). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BSCL2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects BSCL2 function (PMID: 14981520, 17387721, 18585921, 21957196, 22045697, 24345054). For these reasons, this variant has been classified as Pathogenic. (less)
|
|
Pathogenic
(Jun 09, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Clinical Genetics Laboratory, Skane University Hospital Lund
Accession: SCV005196957.1
First in ClinVar: Aug 25, 2024 Last updated: Aug 25, 2024 |
|
|
Pathogenic
(Aug 17, 2015)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Athena Diagnostics
Accession: SCV000612493.1
First in ClinVar: Dec 06, 2016 Last updated: Dec 06, 2016 |
|
|
Pathogenic
(May 31, 2018)
|
criteria provided, single submitter
Method: curation
|
Hereditary spastic paraplegia 17
Affected status: unknown
Allele origin:
unknown
|
SIB Swiss Institute of Bioinformatics
Accession: SCV000803451.1
First in ClinVar: Aug 20, 2018 Last updated: Aug 20, 2018 |
Comment:
This variant is interpreted as a Pathogenic, for Spastic paraplegia 17, autosomal dominant, in Autosomal Dominant manner. The following ACMG Tag(s) were applied: PS4 => … (more)
This variant is interpreted as a Pathogenic, for Spastic paraplegia 17, autosomal dominant, in Autosomal Dominant manner. The following ACMG Tag(s) were applied: PS4 => Prevalence in affecteds statistically increased over controls. N88S is the most frequent mutation. According to Ito & Suzuki 2009, 40 patients out of 48 patients from 16 families have N88S. In ExAC: 1 individual with N88S out of 60000 (PMID:18790819). PS3 => Well-established functional studies show a deleterious effect (PMID:17387721) (PMID:21750110). (less)
|
|
Pathogenic
(-)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary spastic paraplegia 17
Affected status: yes
Allele origin:
unknown
|
Paris Brain Institute, Inserm - ICM
Accession: SCV001451143.1
First in ClinVar: May 16, 2021 Last updated: May 16, 2021 |
Number of individuals with the variant: 3
|
|
Pathogenic
(May 29, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Not Provided
Affected status: yes
Allele origin:
germline
|
GeneDx
Accession: SCV000329928.6
First in ClinVar: Dec 06, 2016 Last updated: Jun 10, 2023 |
Comment:
Published functional studies demonstrate protein over-expression and impairment of synaptic neurotransmission (Windpassinger et al., 2004; Wei et al., 2014); In silico analysis supports that this … (more)
Published functional studies demonstrate protein over-expression and impairment of synaptic neurotransmission (Windpassinger et al., 2004; Wei et al., 2014); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 17387721, 21750110, 22045697, 21957196, 18585921, 14981520, 18612770, 24345054, 16427281, 23553728, 19396477, 31589614, 31211173, 27549087, 29269637, 25219579, 27738760, 25454168, 20598714, 34085946, 32320108, 15732094) (less)
|
|
Pathogenic
(Jun 06, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Inborn genetic diseases
Affected status: unknown
Allele origin:
germline
|
Ambry Genetics
Accession: SCV002743361.2
First in ClinVar: Nov 29, 2022 Last updated: May 01, 2024 |
Comment:
The c.263A>G (p.N88S) alteration is located in exon 3 (coding exon 2) of the BSCL2 gene. This alteration results from an A to G substitution … (more)
The c.263A>G (p.N88S) alteration is located in exon 3 (coding exon 2) of the BSCL2 gene. This alteration results from an A to G substitution at nucleotide position 263, causing the asparagine (N) at amino acid position 88 to be replaced by a serine (S)._x000D_ _x000D_ Based on the available evidence, the BSCL2 c.263A>G (p.N88S) alteration is classified as pathogenic for autosomal dominant BSCL2-related neurologic disorder; however, its clinical significance for autosomal recessive BSCL2-related syndrome is unclear. Based on data from gnomAD, the G allele has an overall frequency of 0.002% (4/251364) total alleles studied. The highest observed frequency was 0.01% (1/10074) of Ashkenazi Jewish alleles. This variant has been reported in multiple individuals with features of autosomal dominant BSCL2-related neurologic disorder and cosegregates with disease in multiple families (Thomas, 2022; Gentile, 2021; Fernández-Eulate, 2020; Minami, 2018; Musacchio, 2017; Ollivier, 2015; Monteiro, 2015; Rakoevi-Stojanovi, 2010; Brusse, 2009; Cafforio, 2008; van de Warrenburg, 2006; Auer-Grumbach, 2005; Windpassinger, 2004). This amino acid position is highly conserved in available vertebrate species. In vitro and in vivo functional studies demonstrate that this alteration disrupts the N-glycosylation site of seipin resulting in protein misfolding and accumulation consistent with a toxic gain-of-function effect (Lundin, 2006; Ito, 2007; Windpassinger, 2004; Ito, 2008; Fei, 2011; Yagi, 2011; Ito, 2012). Additional functional studies show aberrant neuronal electrophysiology and synaptic plasticity in vitro (Wei, 2014). This alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. (less)
|
|
Pathogenic
(Mar 01, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
CeGaT Center for Human Genetics Tuebingen
Accession: SCV001247774.26
First in ClinVar: May 12, 2020 Last updated: Oct 20, 2024 |
Comment:
BSCL2: PP1:Strong, PM2, PS4:Moderate, PP4, PS3:Supporting
Number of individuals with the variant: 6
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Genome Diagnostics Laboratory, University Medical Center Utrecht
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001928302.1 First in ClinVar: Sep 26, 2021 Last updated: Sep 26, 2021 |
|
|
Uncertain significance
(Jan 06, 2016)
|
no assertion criteria provided
Method: literature only
|
Berardinelli-Seip congenital lipodystrophy
Affected status: yes
Allele origin:
germline
|
Inherited Neuropathy Consortium Ii, University Of Miami
Accession: SCV004011965.1
First in ClinVar: Jul 16, 2023 Last updated: Jul 16, 2023 |
|
|
Pathogenic
(Jun 01, 2013)
|
no assertion criteria provided
Method: literature only
|
SILVER SPASTIC PARAPLEGIA SYNDROME
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000024977.7
First in ClinVar: Apr 04, 2013 Last updated: Oct 21, 2023 |
Comment on evidence:
In affected members of 1 English and 4 Austrian families with Silver spastic paraplegia syndrome (SPG17; 270685), Windpassinger et al. (2004) identified heterozygosity for a … (more)
In affected members of 1 English and 4 Austrian families with Silver spastic paraplegia syndrome (SPG17; 270685), Windpassinger et al. (2004) identified heterozygosity for a 263A-G transition (c.263A-G, NM_032667) in the BSCL2 gene, resulting in an asn88-to-ser (N88S) mutation. The English family was the original one reported by Silver (1966). In affected members of 1 Italian, 1 English, and 8 Austrian families with autosomal dominant distal hereditary motor neuronopathy-13 (HMND13; 619112), they identified the N88S mutation. Auer-Grumbach et al. (2005) reported the phenotypic findings in 90 patients from 1 large Austrian family and 2 unrelated German families with the N88S mutation. There was considerable phenotypic variability, including asymptomatic nonpenetrance (4.4%), subclinical involvement (20%), distal spinal muscular atrophy characterized by prominent hand muscle involvement (31.1%), Silver syndrome (14.5%) with hand muscle involvement and spasticity, a Charcot-Marie-Tooth-like phenotype with distal muscle weakness and wasting of the lower limbs and sensory abnormalities (20%), and spastic paraparesis without hand involvement (10%). Auer-Grumbach et al. (2005) concluded that the N88S mutation causes a motor neuron disease affecting the upper motor neurons, lower motor neurons, or both. Hand muscle involvement was a frequent, although not regular, feature, and sensory involvement was usually not present. Genealogic studies of the Austrian kindred traced the disease to a common parent pair born in 1682. Van de Warrenburg et al. (2006) reported 2 Dutch families with multiple affected individuals carrying a heterozygous N88S mutation. The phenotype in both families overlapped between Silver syndrome and HMND13. Affected members in both families had foot and lower limb atrophy with slowly progressive hyperreflexia and extensor plantar responses without prominent spasticity. Hand involvement occurred in most patients and was restricted to interosseus muscles. Brusse et al. (2009) reported 12 members of a large 3-generation Dutch family with phenotypic overlap between Silver syndrome and distal HMND13 who carried a heterozygous N88S mutation. The phenotype was variable, and the distribution of muscle weakness and atrophy included predominantly the feet (in 4), the hands (in 1), or both upper and lower extremities (in 4). Three individuals showed evidence of pyramidal features, including spasticity, hyperreflexia, and extensor plantar responses. Severity of the disease ranged from adolescent patients with disabling muscle weakness to an elderly patient with only mild weakness of the ankle dorsiflexors and bilateral pes cavus. Brusse et al. (2009) noted the extreme phenotypic variability associated with the N88S mutation in their family and in those reported by Auer-Grumbach et al. (2005) and van de Warrenburg et al. (2006), and suggested the presence of other genetic or environmental factors. In their family, Brusse et al. (2009) used genomewide linkage analysis to identify a candidate disease modifier on chromosome 16p13.3-p13.12 between SNPs rs6500882 and rs7192086 that was shared by all 12 affected individuals (maximum lod score of 3.28). One family member without the N88S mutation but with the chromosome 16p haplotype showed mild electrophysiologic abnormalities. Brusse et al. (2009) postulated that a locus on chromosome 16p may contain a disease modifier in their family. Chaudhry et al. (2013) identified a heterozygous N88S mutation in a man with SPG17. He had onset of weakness of the hands and feet at around 12 years of age. Examination at age 14 showed distal weakness and wasting with clawed hands and flat feet, extensor plantar responses, mild tremor, and distal sensory impairment. The disorder was slowly progressive, and he remained ambulatory with orthotics at age 36. His affected uncle also carried the mutation, as did his unaffected mother, suggesting incomplete penetrance. The mutation was identified by exome sequencing of the proband. The family was originally reported by Ionasescu et al. (1991) as having an X-linked form of CMT (302802). (less)
|
|
Pathogenic
(Jun 01, 2013)
|
no assertion criteria provided
Method: literature only
|
NEURONOPATHY, DISTAL HEREDITARY MOTOR, AUTOSOMAL DOMINANT 13
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV004046656.1
First in ClinVar: Oct 21, 2023 Last updated: Oct 21, 2023 |
Comment on evidence:
In affected members of 1 English and 4 Austrian families with Silver spastic paraplegia syndrome (SPG17; 270685), Windpassinger et al. (2004) identified heterozygosity for a … (more)
In affected members of 1 English and 4 Austrian families with Silver spastic paraplegia syndrome (SPG17; 270685), Windpassinger et al. (2004) identified heterozygosity for a 263A-G transition (c.263A-G, NM_032667) in the BSCL2 gene, resulting in an asn88-to-ser (N88S) mutation. The English family was the original one reported by Silver (1966). In affected members of 1 Italian, 1 English, and 8 Austrian families with autosomal dominant distal hereditary motor neuronopathy-13 (HMND13; 619112), they identified the N88S mutation. Auer-Grumbach et al. (2005) reported the phenotypic findings in 90 patients from 1 large Austrian family and 2 unrelated German families with the N88S mutation. There was considerable phenotypic variability, including asymptomatic nonpenetrance (4.4%), subclinical involvement (20%), distal spinal muscular atrophy characterized by prominent hand muscle involvement (31.1%), Silver syndrome (14.5%) with hand muscle involvement and spasticity, a Charcot-Marie-Tooth-like phenotype with distal muscle weakness and wasting of the lower limbs and sensory abnormalities (20%), and spastic paraparesis without hand involvement (10%). Auer-Grumbach et al. (2005) concluded that the N88S mutation causes a motor neuron disease affecting the upper motor neurons, lower motor neurons, or both. Hand muscle involvement was a frequent, although not regular, feature, and sensory involvement was usually not present. Genealogic studies of the Austrian kindred traced the disease to a common parent pair born in 1682. Van de Warrenburg et al. (2006) reported 2 Dutch families with multiple affected individuals carrying a heterozygous N88S mutation. The phenotype in both families overlapped between Silver syndrome and HMND13. Affected members in both families had foot and lower limb atrophy with slowly progressive hyperreflexia and extensor plantar responses without prominent spasticity. Hand involvement occurred in most patients and was restricted to interosseus muscles. Brusse et al. (2009) reported 12 members of a large 3-generation Dutch family with phenotypic overlap between Silver syndrome and distal HMND13 who carried a heterozygous N88S mutation. The phenotype was variable, and the distribution of muscle weakness and atrophy included predominantly the feet (in 4), the hands (in 1), or both upper and lower extremities (in 4). Three individuals showed evidence of pyramidal features, including spasticity, hyperreflexia, and extensor plantar responses. Severity of the disease ranged from adolescent patients with disabling muscle weakness to an elderly patient with only mild weakness of the ankle dorsiflexors and bilateral pes cavus. Brusse et al. (2009) noted the extreme phenotypic variability associated with the N88S mutation in their family and in those reported by Auer-Grumbach et al. (2005) and van de Warrenburg et al. (2006), and suggested the presence of other genetic or environmental factors. In their family, Brusse et al. (2009) used genomewide linkage analysis to identify a candidate disease modifier on chromosome 16p13.3-p13.12 between SNPs rs6500882 and rs7192086 that was shared by all 12 affected individuals (maximum lod score of 3.28). One family member without the N88S mutation but with the chromosome 16p haplotype showed mild electrophysiologic abnormalities. Brusse et al. (2009) postulated that a locus on chromosome 16p may contain a disease modifier in their family. Chaudhry et al. (2013) identified a heterozygous N88S mutation in a man with SPG17. He had onset of weakness of the hands and feet at around 12 years of age. Examination at age 14 showed distal weakness and wasting with clawed hands and flat feet, extensor plantar responses, mild tremor, and distal sensory impairment. The disorder was slowly progressive, and he remained ambulatory with orthotics at age 36. His affected uncle also carried the mutation, as did his unaffected mother, suggesting incomplete penetrance. The mutation was identified by exome sequencing of the proband. The family was originally reported by Ionasescu et al. (1991) as having an X-linked form of CMT (302802). (less)
|
|
pathogenic
(-)
|
no assertion criteria provided
Method: not provided
|
Distal hereditary motor neuronopathy type 5
Affected status: not provided
Allele origin:
germline
|
Northcott Neuroscience Laboratory, ANZAC Research Institute
Accession: SCV000188719.1
First in ClinVar: Sep 04, 2014 Last updated: Sep 04, 2014
Comment:
Family G and H
|
Comment:
Converted during submission to Pathogenic.
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Clinical Genetics, Academic Medical Center
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001919334.1 First in ClinVar: Sep 26, 2021 Last updated: Sep 26, 2021 |
|
|
not provided
(-)
|
no classification provided
Method: literature only
|
Hereditary spastic paraplegia 17
Affected status: unknown
Allele origin:
germline
|
GeneReviews
Accession: SCV002574753.1
First in ClinVar: Sep 24, 2022 Last updated: Sep 24, 2022 |
|
|
click to load more click to collapse |
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
High efficiency and clinical relevance of exome sequencing in the daily practice of neurogenetics. | Thomas Q | Journal of medical genetics | 2022 | PMID: 34085946 |
Rare among Rare: Phenotypes of Uncommon CMT Genotypes. | Gentile L | Brain sciences | 2021 | PMID: 34942918 |
Phenotypic correlations in a large single-center cohort of patients with BSCL2 nerve disorders: a clinical, neurophysiological and muscle magnetic resonance imaging study. | Fernández-Eulate G | European journal of neurology | 2020 | PMID: 32320108 |
The First Report of a Japanese Case of Seipinopathy with a BSCL2 N88S Mutation. | Minami K | Internal medicine (Tokyo, Japan) | 2018 | PMID: 29269637 |
BSCL2-Related Neurologic Disorders / Seipinopathy. | Adam MP | - | 2018 | PMID: 20301484 |
ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia. | Musacchio T | Journal of neurology | 2017 | PMID: 27738760 |
Clinical and electrophysiological features in a French family presenting with seipinopathy. | Ollivier Y | Neuromuscular disorders : NMD | 2015 | PMID: 25454168 |
BSCL2 N88S mutation in a Portuguese patient with the Silver syndrome. | Monteiro A | Muscle & nerve | 2015 | PMID: 25219579 |
Motor neuropathy-associated mutation impairs Seipin functions in neurotransmission. | Wei S | Journal of neurochemistry | 2014 | PMID: 24345054 |
Re-analysis of an original CMTX3 family using exome sequencing identifies a known BSCL2 mutation. | Chaudhry R | Muscle & nerve | 2013 | PMID: 23553728 |
Seipin: from human disease to molecular mechanism. | Cartwright BR | Journal of lipid research | 2012 | PMID: 22474068 |
Characterization of inclusion bodies with cytoprotective properties formed by seipinopathy-linked mutant seipin. | Ito D | Human molecular genetics | 2012 | PMID: 22045697 |
Molecular characterization of seipin and its mutants: implications for seipin in triacylglycerol synthesis. | Fei W | Journal of lipid research | 2011 | PMID: 21957196 |
N88S seipin mutant transgenic mice develop features of seipinopathy/BSCL2-related motor neuron disease via endoplasmic reticulum stress. | Yagi T | Human molecular genetics | 2011 | PMID: 21750110 |
N88S mutation in the BSCL2 gene in a Serbian family with distal hereditary motor neuropathy type V or Silver syndrome. | Rakocević-Stojanović V | Journal of the neurological sciences | 2010 | PMID: 20598714 |
A novel 16p locus associated with BSCL2 hereditary motor neuronopathy: a genetic modifier? | Brusse E | Neurogenetics | 2009 | PMID: 19396477 |
Seipinopathy: a novel endoplasmic reticulum stress-associated disease. | Ito D | Brain : a journal of neurology | 2009 | PMID: 18790819 |
The first Italian family with evidence of pyramidal impairment as phenotypic manifestation of Silver syndrome BSCL2 gene mutation. | Cafforio G | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | 2008 | PMID: 18612770 |
Characterization of seipin/BSCL2, a protein associated with spastic paraplegia 17. | Ito D | Neurobiology of disease | 2008 | PMID: 18585921 |
Molecular pathogenesis of seipin/BSCL2-related motor neuron diseases. | Ito D | Annals of neurology | 2007 | PMID: 17387721 |
Membrane topology of the human seipin protein. | Lundin C | FEBS letters | 2006 | PMID: 16574104 |
BSCL2 mutations in two Dutch families with overlapping Silver syndrome-distal hereditary motor neuropathy. | van de Warrenburg BP | Neuromuscular disorders : NMD | 2006 | PMID: 16427281 |
Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. | Auer-Grumbach M | Annals of neurology | 2005 | PMID: 15732094 |
Gene and phenotype analysis of congenital generalized lipodystrophy in Japanese: a novel homozygous nonsense mutation in seipin gene. | Ebihara K | The Journal of clinical endocrinology and metabolism | 2004 | PMID: 15126564 |
Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. | Windpassinger C | Nature genetics | 2004 | PMID: 14981520 |
Heterogeneity in X-linked recessive Charcot-Marie-Tooth neuropathy. | Ionasescu VV | American journal of human genetics | 1991 | PMID: 1674639 |
Familial spastic paraplegia with amyotrophy of the hands. | Silver JR | Annals of human genetics | 1966 | PMID: 5964029 |
click to load more click to collapse |
Text-mined citations for rs137852972 ...
HelpRecord last updated Oct 20, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.